Prognostic impact of mutation profiling in patients with stage II and III colon cancer.

doi:10.1038/srep24310

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Prognostic impact of mutation profiling in patients with stage II and III colon cancer.

Scientific reports - 14 Apr 2016

Shen Yinchen, Han Xiaohong, Wang Jianfei, Wang Shuai, Yang Hongying, Lu Shih-Hsin, Shi Yuankai

Abstract excerpt

Development of colorectal cancer (CRC) associates with accumulation of genetic mutations include the epidermal growth factor receptor (EGFR) signaling pathway. However, whether mutations in KRAS together with downstream factors BRAF, PIK3CA and NRAS impact prognosis is still unclear for stage II-III colon cancer. In the present study a total of 228 stage II-III colon cancer samples were retrospectively collected,...

Topics

Colonic Neoplasms
Genotype
Humans
Mutation
Neoplasm Staging
Pathology, Molecular
Prognosis
Retrospective Studies
Sequence Analysis, DNA

Source

Open in PubMed Open full text

Identifiers

PMID: 27074743
DOI: 10.1038/srep24310
PMCID: PMC4830995

Genes

BRAF
KRAS
NRAS
EGFR

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.